BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36037364)

  • 1. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.
    Xie H; Zhou J; Liu X; Xu Y; Hepperla AJ; Simon JM; Wang T; Yao H; Liao C; Baldwin AS; Gong K; Zhang Q
    Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2119854119. PubMed ID: 36037364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP37 promotes deubiquitination of HIF2α in kidney cancer.
    Hong K; Hu L; Liu X; Simon JM; Ptacek TS; Zheng X; Liao C; Baldwin AS; Zhang Q
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13023-13032. PubMed ID: 32461361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
    Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
    Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
    Zhu L; Ding R; Yan H; Zhang J; Lin Z
    Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L; Yang H
    PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer.
    Fang W; Liao C; Shi R; Simon JM; Ptacek TS; Zurlo G; Ye Y; Han L; Fan C; Bao L; Ortiz CL; Lin HR; Manocha U; Luo W; Peng Y; Kim WY; Yang LW; Zhang Q
    Elife; 2021 Nov; 10():. PubMed ID: 34779768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
    J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
    Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
    Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
    Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
    Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
    Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.